

Overview: Role of MIE in Shaping FDA Product-Specific Guidances

Ross Walenga, PhD

Senior Chemical Engineer

Division of Quantitative Methods and Modeling,

Office of Research and Standards, Office of Generic Drugs

Center for Drug Evaluation and Research | U.S. Food and Drug Administration

Advancing Generic Drug Development (AGDD): Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Complex Generic Drugs – August 27, 2026

The Use of MIE Within FDA

For generic drug products, PSG recommendations can be informed by MIE.

Such MIE is generated by FDA employees as well as external sources, such as research collaborators or industry.

While this session will focus on application of PBPK models, other modeling approaches may be used to generate MIE as well.

MIE – model-integrated evidence

PSG – product-specific guidance

PBPK – physiologically based pharmacokinetics

How MIE Shapes PSG Recommendations



MIE can provide information on:

- In vitro-in vivo relationships (IVIVRs)
- Virtual bioequivalence (BE)

This information can then:

- Identify alternatives to in vivo BE studies
- Facilitate streamlined in vivo study designs
- Support post-approval changes and biowaivers

Overarching Guidance

The ICH* M15 Guidance: General Principles for Model-Informed Drug Development

Provides a harmonized
framework for model
assessment and documentation
standards.

Model Risk

“Contribution of the model
outcomes to a possible wrong
decision and subsequent potential
undesirable consequences.”

It is essential for determining the
requirements of model evaluation.

* - *International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use*

Session Presentations



In Silico Modeling to Guide Charcoal Block PK BE Study Recommendations for Orally Inhaled Drug Products

Ross Walenga, PhD

PBPK Modeling to Support Product-Specific Guidance Revision for Cabotegravir Long-Acting Injectable Suspension

Khondoker Alam, PhD

PBPK/Pharmacodynamic Modeling to Support Product-Specific Guidance Development for Ophthalmic Drugs

Mingliang Tan, PhD

Session Presentations (cont'd)

PBPK Absorption Modeling to Support General and Product-Specific Guidance Development

Fang Wu, PhD

The ICH M15 Guidance: Assessment of Model-Informed Drug Development (MIDD) Evidence

Colleen Kuemmel, PhD



References

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. M15 General Principles for Model-Informed Drug Development. (Recommended February 2026). Available from: <https://www.ich.org/news/harmonised-ich-m15-guideline-general-principles-model-informed-drug-development-adopted>. Accessed June 10, 2026.
2. ASME V&V 40-2018: Assessing credibility of computational modeling through verification and validation: Application to medical devices. New York, NY: American Society of Mechanical Engineers; 2018.